INVICTUS ANNOUNCES AB LABORATORIES INC. UPDATE
26 6월 2019 - 10:44PM
Vancouver, BC, June 26, 2019 - INVICTUS MD STRATEGIES
CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA:
8IS2) Mr. Trevor Dixon, Chief Executive Officer of
Invictus, is pleased to report that AB Laboratories Inc. (“AB
Labs”), a company which is a 50% owned subsidiary of Invictus
has completed construction of their 40,000 sq. ft. custom built
cultivation facility located near Hamilton, Ontario. AB Labs’
facility contains ten identical cultivation rooms capable of
producing over 65 crops annually on a tightly controlled weekly
production schedule.
Mr. Marc Ripa, Chief Operating Officer of Invictus and Chief
Executive Officer of AB Labs and the other 50% owner of AB Labs
stated, “It has been a long road to completion, but we are
extremely excited about the end product. AB Labs submitted their
evidence package to Health Canada on June 4, 2019 to amend its
license to include the new facility. I will continue to work
closely with Health Canada to expedite the start of
production.”
Mr. Ripa continued, “AB Labs is focused on producing high
quality products within a highly automated production environment.
AB Labs Phase I facility has been in full production since January
1, 2017 and continues to work on a strict production schedule
yielding crops on a monthly basis. The Phase I research and
development on strain varieties continues with great success.
AB Labs is currently offering fifteen strain varieties to their
registered medical clients”.
AB Labs became a Licensed Producer under the Access to Cannabis
for Medical Purposes Regulations (“ACMPR”) on October 21,
2016. AB Labs also received its sales license pursuant to the
ACMPR, effective January 5, 2019. On October 22, 2017, Health
Canada extended the existing ACMPR license for a period of two
years. AB Labs applied for the renewal of their license under
the Cannabis Act, which replaced the ACMPR, for an additional 3
years on June 21, 2019.
On Behalf of the Board
Trevor Dixon
Chief Executive Officer
Investor Relations 1-844-800-6086
E-Mail: connect@invictus-md.com
About Invictus
Invictus is a global cannabis company with a focus on the
Canadian cannabis space, offering a selection of products under a
wide range of cannabinoid profiles that fit the demand of the
Company’s medical clients and retail customers. The Company’s
integrated sales approach is defined by five pillars of
distribution including medical, adult-use, international, Licensed
Producer to Licensed Producer and sales to provinces.
To meet growing demand, Invictus is expanding its cultivation
footprint with three cannabis production facilities licensed under
the Cannabis Act, which replaced the Access to Cannabis for Medical
Purposes Regulations (“ACMPR”) in Canada. Invictus’
wholly-owned subsidiary, Acreage Pharms Ltd.’s (“Acreage”) Phase I
and Phase II facilities are in full production and Acreage is
completing its Phase III cultivation facility. Invictus’ wholly
owned subsidiary 0989561 B.C. Ltd. (dba Canandia Bioceuticals)
Delta facility is a licensed producer and has received its sales
license issued by Health Canada under the Cannabis Act.
Another of Invictus’ wholly owned subsidiaries, 2015059 Alberta
Ltd. (dba Leaf Wise), continues to connect medical clients to
physicians for medical cannabis and to Invictus’ fully licensed
cannabis producers under the Cannabis Act. Future Harvest
Development Ltd., a company which is a 82.5% owned subsidiary of
Invictus continues to produce high-quality fertilizer and nutrients
which are supplied to licensed cannabis producers. Invictus is
targeting up to 50 percent of production to medical cannabis.
Invictus drives sustainable long-term shareholder value by
continuing to develop Invictus’ Canadian production of medical and
recreational cannabis products. For more information
visit www.invictus-md.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
Kathy Love
Invictus MD Strategies Corp.
kathy@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Invictus MD Strategies (TSXV:GENE)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
